New developments in epidemiology, diagnosis, and treatment of fascioliasis

Current Opinion in Infectious Diseases

Volumn 25, Issue 5, 2012, Pages 518-522

  Cabada, Miguel M ^a   White, A Clinton ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

Fasciola hepatica; trematode; triclabendazole; zoonosis

Indexed keywords

ANTIPARASITIC AGENT; ARTEMETHER; ARTESUNATE; DNA POLYMERASE; IMMUNOGLOBULIN G ANTIBODY; IVERMECTIN; MONOCLONAL ANTIBODY; OXFENDAZOLE; OZ 78; PARASITE ANTIGEN; RECOMBINANT ANTIGEN; TRICLABENDAZOLE; UNCLASSIFIED DRUG;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; ANTIGEN DETECTION; CATERING SERVICE; CHILD NUTRITION; CONTRAST ENHANCEMENT; DAILY LIFE ACTIVITY; DAIRY INDUSTRY; DEVELOPING COUNTRY; DIAGNOSTIC TEST; DNA DETERMINATION; DRUG EFFICACY; DRUG POTENTIATION; EARLY DIAGNOSIS; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FASCIOLA GIGANTICA; FASCIOLA HEPATICA; FASCIOLIASIS; HEALTH CARE ACCESS; HUMAN; LIVESTOCK; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MILK PRODUCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PREVALENCE; RADIODIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SINGLE DRUG DOSE; SLAUGHTERHOUSE;

ANTHELMINTICS; ANTIBODIES, HELMINTH; BENZIMIDAZOLES; COST OF ILLNESS; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASCIOLIASIS; HUMANS; POINT-OF-CARE SYSTEMS;

EID: 84865860434     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283567b7e     Document Type: Review

References (41)

1. Fü rst T, Keiser J, Utzinger J. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:210-221.
2. Parkinson M, O'Neill SM, Dalton JP. Endemic human fasciolosis in the Bolivian Altiplano. Epidemiol Infect 2006; 26:1-6.
3. Nguyen TG, Le TH, De NV, et al. Assessment of a 27-kDa antigen in enzyme linked immunosorbent assay for the diagnosis of fasciolosis in Vietnamese patients. Trop Med Int Health 2010; 15:462-467.
4. Curtale F, Hassanein YAW, Barduagni P, et al. Human fascioliasis infection: gender differences within school-age children from endemic areas of the Nile Delta, Egypt. Trans R Soc Trop Med Hyg 2007; 101:155-160.
5. Curtale F, Hasanein YA, Savioli L. Control of human fascioliasis by selective chemotherapy: design, cost, and effect of the first public health, school-based intervention implemented in endemic areas of Nile Delta, Egypt. Trans R Soc Trop Med Hyg 2005; 99:599-609.
6. Rokni MB, Massoud J, O'Neill SM, et al. Diagnosis of human fasciolosis in the Gilan province of Northern Iran: application of cathepsin L-ELISA. Diagn Microbiol Infect Dis 2002; 44:175-179.
7. Kaya M, Bestas R, Cetin S. Clinical presentation and management of Fasciola hepatica infection: single-center experience. World J Gastroenterol 2011; 17:4899-4904.
8. Makki SM, Arafa WAS. Parasitosis among apparently healthy immigrant workers at Damman, Saudi Arabia. J Egypt Soc Parasitol 2010; 40:311-320.
9. Mohammad KAH, Koshal EAK. A prospective study on parasites among expatriate workers in Al-Baha from 2009-2011, Saudi Arabia. J Egypt Soc Parasitol 2011; 41:423-432.
10. Mera y Sierra R, Agramunt VH, Cuervo P, Mas-Coma S. Human fascioliasis in Argentina: retrospective overview, critical analysis and baseline for future research. Parasit Vectors 2011; 4:104.
11. Bargues MD, Gonzá lez LC, Artigas P, Mas-Coma S. A new baseline for fascioliasis in Venezuela: lymnaeid vectors ascertained by DNA sequencing and analysis of their relationships with human and animal infection. Parasit Vectors 2011; 4:200.
12. Agnamey P, Fortes-Lopes E, Raccurt CP, et al. Cross-sectional serological survey of human fascioliasis in Haiti. J Parasitol Res 2012; 2012:751951.
13. Espinoza JR, Terashima A, Herrera-Velit P, Marcos LA. Human and animal fascioliasis in Peru: impact in the economy of endemic zones. Rev Peru Med Exp Salud Publica 2010; 27:604-612.
14. Valero MA, Perez-Crespo I, Khoubbane M, et al. Fasciola hepatica phenotypic characterization in Andean human endemic areas: valley versus altiplanic patterns analysed in liver flukes from sheep from Cajamarca and Mantaro, Peru. Infect Genet Evol 2012; 12:403-410.
15. Gonzalez LC, Esteban JG, Barques MD, et al. Hyperendemic human fasciolasis in Andean valleys; an altitudinal transect analysis in children of Cajamarca province, Peru. Acta Trop 2011; 120:119-129.
16. Lopez M, White AC Jr, Cabada MM. Burden of Fasciola hepatica infection among children from Paucartambo in Cusco, Peru. Am J Trop Med Hyg 2012; 86:481-485.
17. Karahocagil MK, Akdeniz H, Sunnetcioglu M, et al. A familial outbreak of fascioliasis in Eastern Anatolia: a report with review of literature. Acta Trop 2011; 118:177-183.
18. Bernardo CC, Carneiro MB, Avelar BR, et al. Prevalence of liver condemnation due to bovine fasciolosis in Southern Esp?́rito Santo: temporal distribution and economic losses. Rev Bras Parasitol Vet 2011; 20:49-53.
19. Blanco-Penedo I, Hö glund J, Fall N, Emanuelson U. Exposure to pasture borne nematodes affects individual milk yield in Swedish dairy herds. Vet Parasitol 2012. [Epub ahead of print]
20. Rowan SE, Levi ME, Youngwerth JM, et al. The variable presentations and broadening geography of hepatic fascioliasis. Clin Gastroenterol Hepatol 2012. [Epub ahead of print]
21. Cantisani V, Cantisani C, Mortelé K, et al. Diagnostic imaging in the study of human hepatobiliary fascioliasis. Radiol Med 2010; 115:83-92.
22. Keiser J, Duthaler U, Utzinger J. Update on the diagnosis and treatment of food-borne trematode infections. Curr Opin Infect Dis 2010; 23:513-520.
23. Adela Valero M, Victoria Periago M, Pé rez-Crespo I, et al. Assessing the validity of an ELISA test for the serological diagnosis of human fascioliasis in different epidemiological situations. Trop Med Int Health 2012. doi: 10.1111/j.1365-3156.2012.02964.x. [Epub ahead of print]
24. Figueroa-Santiago O, Delgado B, Espino AM. Fasciola hepatica saposin-like protein-2-based ELISA for the serodiagnosis of chronic human fascioliasis. Diagn Microbiol Infect Dis 2011; 70:355-361.
25. Anuracpreeda P, Wanichanon C, Chawengkirtikul R, et al. Fasciola gigantica: immunodiagnosis of fasciolosis by detection of circulating 28.5 kDa tegumental antigen. Exp Parasitol 2009; 123:334-340.
26. Ubeira FM, Muiño L, Valero MA, et al. MM3-ELISA detection of Fasciola hepatica coproantigens in preserved human stool samples. Am J Trop Med Hyg 2009; 81:156-162.
27. Demerdash ZA, Diab TM, Aly IR, et al. Diagnostic efficacy of monoclonal antibody based sandwich enzyme linked immunosorbent assay (ELISA) for detection of Fasciola gigantica excretory/secretory antigens in both serum and stool. Parasit Vectors 2011; 4:176.
28. Ai L, Chen MX, Alasaad S, et al. Genetic characterization, species differentiation and detection of Fasciola spp. by molecular approaches. Parasit Vectors 2011; 4:101.
29. Rodríguez DC, Pino N, Peñ uela G. Microbiological quality indicators in waters of dairy farms: Detection of pathogens by PCR in real time. Sci Total Environ 2012; 427-428:314-318.
30. Prasad PK, Goswami LM, Tandon V, Chatterjee A. PCR-based molecular characterization and in silico analysis of food-borne trematode parasites Paragonimus westermani, Fasciolopsis buski and Fasciola gigantica from Northeast India using ITS2 rDNA. Bioinformation 2011; 6:64-68.
31. Alasaad S, Soriguer RC, Abu-Madi M, et al. A TaqMan real-time PCR-based assay for the identification of Fasciola spp. Vet Parasitol 2011; 179:266-271.
32. Ai L, Li C, Elsheikha HM, et al. Rapid identification and differentiation of Fasciola hepatica and Fasciola gigantica by a loop-mediated isothermal amplification (LAMP) assay. Vet Parasitol 2010; 174:228-233.
33. Gupta A, Dixit AK, Dixit P, et al. Evaluation of dipstick-ELISA using 28 kDa Fasciola gigantica cathepsin L-cysteine proteinase (FgCL3) for serodiagnosis of fasciolosis in naturally infected goats. Vet Parasitol 2011; 176:165-169.
34. Ali NM. Development and evaluation of a dipstick assay in diagnosis of human fasciolosis. Parasitol Res 2012; 110:1649-1654.
35. Martínez-Sernández V, Muiño L, Perteguer MJ, et al. Development and evaluation of a new lateral flow immunoassay for serodiagnosis of human fasciolosis. PLoS Negl Trop Dis 2011; 5:e1376.
36. World Health Organization 2006. Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control. WHO Headquarters, Switzerland. Available at http://www.who.int/neglected-diseases/preventive-chemotherapy/WHO- CDS-NTD-PCT-2007.1.pdf accessed 05/02/2012.
37. Fairweather I. Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy? Vet Parasitol 2011; 180:133-143.
38. Duthaler U, Smith TA, Keiser J. In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78. Antimicrob Agents Chemother 2010; 54:4596-4604.
39. Diab TM, Mansour HH, Mahmoud SS. Fasciola gigantica: parasitological and scanning electron microscopy study of the in vitro effects of ivermectin and/or artemether. Exp Parasitol 2010; 124:279-284.
40. Keiser J, Sayed H, El-Ghanam M, et al. Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials. PLoS Negl Trop Dis 2011; 5:e1285.
41. Gomez-Puerta LA, Gavidia C, Lopez-Urbina MT, et al.; Cysticercosis Working Group in Peru. Efficacy of a single oral dose of oxfendazole against Fasciola hepatica in naturally infected sheep. Am J Trop Med Hyg 2012; 86:486-488.